All Major Solid Tumors
Cancer Type
Tumor Tissue (FFPE)
Specimen Requirements
10 Working Days
Turnaround Time ¹
ACTFusion™ is a targeted, multi-biomarker assay that examines 13 druggable fusion genes, and more than 350 known and novel transcripts.
Determine Fusion Status For More Treatment Options
13
Fusion Genes
350
Fusion Transcripts
Hallmarks of ACTFusion™
Comprehensive Testing for More Treatment Options
A targeted, multi-biomarker assay across solid tumors that examines multiple actionable fusion genes, which have either been included in the NCCN guidelines (e.g. ALK, ROS1, RET, FGFR2/3, NTRK1/2/3,and MET exon 14 skipping) or have been included in global clinical trials (e.g.NRG1).
Report Consultation
Complements every report with a face-to-face consultation with an expert from our medical team.
Pioneering Bioinformatics
Integrates cancer biology, medical informatics, molecular biology, cell biology, immunology, bioinformatics, data science and pharmaceutical biology to provide insightful interpretation of the data analyses.
Short Turnaround Time
Provides professional solutions within 10 working days (starting from the date of receipt of approved samples at our CAP-accredited laboratory).
Summary
Find Biomarkers in More Than 350 Fusion Transcripts
Fusion genes are hybrid genes that form as a result of chromosomal rearrangements or abnormal transcription (Figure 1) and are known to be one of the major drivers behind cancer initiation and progression. Gene fusion can be used in the diagnosis of a variety of cancers. In 2018, the FDA approved the first tumor agnostic treatment for those with TRK fusion based on the clinical benefits observed across numerous tumor types (Figure 2). In some cancer types, fusion genes play particularly important roles, for example, over 10% fusion genes were found in NSCLC and over 15% were found in thyroid cancer2,3. ACTFusion™ is a targeted, multi-biomarker assay that examines 13 actionable fusion genes and more than 350 known and novel fusion transcripts, which are either included in the NCCNguidelines (e.g. ALK, ROS1, RET, FGFR2/3, NTRK1/2/3, and MET exon 14 skipping)or have been included in global clinical trials (e.g. NRG1).
Precise Identification of Known and Novel Fusion Transcripts to Maximize Treatment
Of the various fusion transcripts in cancers, many targeted drugs have been developed to inhibit specific fusion transcripts in certain cancer types. The tissue-agnostic TRK inhibitor is a newly developed targeted drug that can overcome the complexity in fusion genes, and has already been applied widely across cancer types. Patients diagnosed with different cancer types with various fusion transcripts exhibited a 75% response rate in a clinical trial studying the TRK inhibitor.5 Precise identification of fusion transcripts provides solid indications among treatment options to maximize effectiveness.
For All Solid Tumors
Selects the most suitable treatment options based on fusion gene status.
Treatment Types
Targeted therapies approved by USFDA or in global clinical trials.
Technical Specifications
Next Generation Sequencing (NGS)
13 fusion genes (more than 350 known and novel fusion transcripts)
Specimen Requirements6
Tumor tissue (FFPE)
Targeted Therapy Evaluation
Eg. ALK, ROS1, NTRK-related fusion genes
Documentation
Disclaimers / Footnotes
- Turnaround time starts from the date of receipt of approved samples at our CAP-accredited laboratory.
- Jordan EJ, et al. (2017) Cancer Discov. 7(6):596-609.
- Cancer Genome Atlas Research Network. (2014) Cell. 159:676-690.
- Zehir A, et al. (2017) Nat Med. 23(6):703-713.
- Drilon A, et al. (2018) N Engl J Med. 378(8):731-739.
- Please refer to our specimen instructions.
